Argininosuccinic Aciduria Market

DelveInsight's "Argininosuccinic Aciduria (ASA) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Argininosuccinic aciduria (ASA), historical and forecasted epidemiology as well as the Argininosuccinic aciduria (ASA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Argininosuccinic aciduria (ASA) market report provides current treatment practices, emerging drugs, Argininosuccinic aciduria (ASA) market share of the individual therapies, current and forecasted Argininosuccinic aciduria (ASA) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Argininosuccinic aciduria (ASA) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Argininosuccinic Aciduria (ASA) Disease Understanding and Treatment Algorithm

The DelveInsight Argininosuccinic aciduria (ASA) market report gives a thorough understanding of the Argininosuccinic aciduria (ASA) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.


Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Argininosuccinic aciduria (ASA).


Treatment

It covers the details of conventional and current medical therapies available in the Argininosuccinic aciduria (ASA) market for the treatment of the condition. It also provides Argininosuccinic aciduria (ASA) treatment algorithms and guidelines in the United States, Europe, and Japan.

Argininosuccinic Aciduria (ASA) Epidemiology 

The Argininosuccinic aciduria (ASA) epidemiology division provide insights about historical and current Argininosuccinic aciduria (ASA) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 


Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Argininosuccinic aciduria (ASA) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Argininosuccinic Aciduria (ASA) Epidemiology

The epidemiology segment also provides the Argininosuccinic aciduria (ASA) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Argininosuccinic Aciduria (ASA) Drug Chapters

Drug chapter segment of the Argininosuccinic aciduria (ASA) report encloses the detailed analysis of Argininosuccinic aciduria (ASA) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Argininosuccinic aciduria (ASA) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.


Marketed Drugs

The report provides the details of the marketed product available for Argininosuccinic aciduria (ASA) treatment.


Argininosuccinic Aciduria (ASA) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Argininosuccinic aciduria (ASA) treatment.

Argininosuccinic Aciduria (ASA) Market Outlook

The Argininosuccinic aciduria (ASA) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Argininosuccinic aciduria (ASA) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.


This segment gives a thorough detail of Argininosuccinic aciduria (ASA) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, Argininosuccinic aciduria (ASA) market in 7MM is expected to change in the study period 2017-2030.


Key Findings

This section includes a glimpse of the Argininosuccinic aciduria (ASA) market in 7MM.


The United States Market Outlook

This section provides the total Argininosuccinic aciduria (ASA) market size and market size by therapies in the United States.


EU-5 Countries: Market Outlook

The total Argininosuccinic aciduria (ASA) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.


Japan Market Outlook

The total Argininosuccinic aciduria (ASA) market size and market size by therapies in Japan is also mentioned.

Argininosuccinic Aciduria (ASA) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Argininosuccinic aciduria (ASA) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Argininosuccinic aciduria (ASA) market uptake by drugs; patient uptake by therapies; and sales of each drug.   


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Argininosuccinic Aciduria (ASA) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Argininosuccinic aciduria (ASA) key players involved in developing targeted therapeutics.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Argininosuccinic aciduria (ASA) emerging therapies.


Reimbursement Scenario in Argininosuccinic Aciduria (ASA)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Argininosuccinic aciduria (ASA) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Argininosuccinic aciduria (ASA) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Argininosuccinic aciduria (ASA) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Argininosuccinic aciduria (ASA), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Argininosuccinic aciduria (ASA) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Argininosuccinic aciduria (ASA) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Argininosuccinic aciduria (ASA) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Argininosuccinic aciduria (ASA) market

Report Highlights

  • In the coming years, Argininosuccinic aciduria (ASA) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Argininosuccinic aciduria (ASA) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
  • Major players are involved in developing therapies for Argininosuccinic aciduria (ASA). Launch of emerging therapies will significantly impact the Argininosuccinic aciduria (ASA) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Argininosuccinic aciduria (ASA)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities


Argininosuccinic Aciduria (ASA) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Argininosuccinic aciduria (ASA) Pipeline Analysis
  • Argininosuccinic aciduria (ASA) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Argininosuccinic Aciduria (ASA) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Argininosuccinic aciduria (ASA) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake


Argininosuccinic Aciduria (ASA) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Argininosuccinic aciduria (ASA) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Argininosuccinic aciduria (ASA) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Argininosuccinic aciduria (ASA) market size during the forecast period (2017-2030)?
  • At what CAGR, the Argininosuccinic aciduria (ASA) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Argininosuccinic aciduria (ASA) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Argininosuccinic aciduria (ASA) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Argininosuccinic aciduria (ASA)?
  • What is the historical Argininosuccinic aciduria (ASA) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Argininosuccinic aciduria (ASA) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Argininosuccinic aciduria (ASA)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Argininosuccinic aciduria (ASA) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Argininosuccinic aciduria (ASA) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Argininosuccinic aciduria (ASA) in the USA, Europe, and Japan?
  • What are the Argininosuccinic aciduria (ASA) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Argininosuccinic aciduria (ASA)?
  • How many therapies are developed by each company for Argininosuccinic aciduria (ASA) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Argininosuccinic aciduria (ASA) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Argininosuccinic aciduria (ASA) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Argininosuccinic aciduria (ASA) and their status?
  • What are the key designations that have been granted for the emerging therapies for Argininosuccinic aciduria (ASA)?
  • What are the global historical and forecasted market of Argininosuccinic aciduria (ASA)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Argininosuccinic aciduria (ASA) market
  • To understand the future market competition in the Argininosuccinic aciduria (ASA) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Argininosuccinic aciduria (ASA) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Argininosuccinic aciduria (ASA) market
  • To understand the future market competition in the Argininosuccinic aciduria (ASA) market

1. Key Insights

2. Executive Summary of Argininosuccinic aciduria (ASA)

3. Competitive Intelligence Analysis for Argininosuccinic aciduria (ASA)

4. Argininosuccinic aciduria (ASA): Market Overview at a Glance

4.1. Argininosuccinic aciduria (ASA) Total Market Share (%) Distribution in 2017

4.2. Argininosuccinic aciduria (ASA) Total Market Share (%) Distribution in 2030

5. Argininosuccinic aciduria (ASA): Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Argininosuccinic aciduria (ASA) Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Argininosuccinic aciduria (ASA) Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Argininosuccinic aciduria (ASA) Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Argininosuccinic aciduria (ASA) Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Argininosuccinic aciduria (ASA) Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Argininosuccinic aciduria (ASA) Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Argininosuccinic aciduria (ASA) Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Argininosuccinic aciduria (ASA) Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Argininosuccinic aciduria (ASA) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Argininosuccinic aciduria (ASA) Treatment and Management

8.2. Argininosuccinic aciduria (ASA) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Argininosuccinic aciduria (ASA) Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Argininosuccinic aciduria (ASA): Seven Major Market Analysis

13.1. Key Findings

13.2. Argininosuccinic aciduria (ASA) Market Size in 7MM

13.3. Argininosuccinic aciduria (ASA) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Argininosuccinic aciduria (ASA) Total Market Size in the United States

15.1.2. Argininosuccinic aciduria (ASA) Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Argininosuccinic aciduria (ASA) Total Market Size in Germany

15.3.2. Argininosuccinic aciduria (ASA) Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Argininosuccinic aciduria (ASA) Total Market Size in France

15.4.2. Argininosuccinic aciduria (ASA) Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Argininosuccinic aciduria (ASA) Total Market Size in Italy

15.5.2. Argininosuccinic aciduria (ASA) Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Argininosuccinic aciduria (ASA) Total Market Size in Spain

15.6.2. Argininosuccinic aciduria (ASA) Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Argininosuccinic aciduria (ASA) Total Market Size in the United Kingdom

15.7.2. Argininosuccinic aciduria (ASA) Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Argininosuccinic aciduria (ASA) Total Market Size in Japan

15.8.3. Argininosuccinic aciduria (ASA) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Argininosuccinic aciduria (ASA)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Table

 Table 1: Upper Limits of Normal Plasma Ammonia Concentration by Age

Table 2: Age-related Plasma Amino Acid Concentrations in ASL Deficiency

Table 3: Proposed monitoring for patients with argininosuccinic aciduria (ASA)

Table 4: Total Incident Population of ASA in 7MM (2017–2030)

Table 5: Total Incident Cases of ASA in the US (2017–2030)

Table 6: Early-onset and Late-onset Cases of ASA in the US (2017–2030)

Table 7: Total Incident Cases of ASA in Germany (2017–2030)

Table 8: Early-onset and Late-onset Cases of ASA in Germany (2017–2030)

Table 9: Total Incident Cases of ASA in France (2017–2030)

Table 10: Early-onset and Late-onset Cases of ASA in France (2017–2030)

Table 11: Total Incident Cases of ASA in Italy (2017–2030)

Table 12: Early-onset and Late-onset Cases of ASA in Italy (2017–2030)

Table 13: Total Incident Cases of ASA in Spain (2017–2030)

Table 14: Early-onset and Late-onset Cases of ASA in Spain (2017–2030)

Table 15: Total Incident Cases of ASA in the UK (2017–2030)

Table 16: Early-onset and Late-onset Cases of ASA in the UK (2017–2030)

Table 17: Total Incident Cases of ASA in Japan (2017–2030)

Table 18: Early-onset and Late-onset Cases of ASA in Japan (2017–2030)

Table 19: Recommended Surveillance for Individuals with Argininosuccinate Lyase Deficiency

Table 20: Key Competitors

Table 21: Ravicti, Clinical Trial Description, 2020

Table 22: Market Size of Argininosuccinic aciduria in 7MM in USD Million (2017–2030)

Table 23: Total Market Size of Argininosuccinic aciduria in the US in USD Million (2017–2030)

Table 24: The US Market Size of ASA by Therapies, in USD Million (2017–2030)

Table 25: Total Market Size of Argininosuccinic aciduria in Germany in USD Million (2017–2030)

Table 26: Germany Market Size of ASA by Therapies, in USD Million (2017–2030)

Table 27: Total Market Size of Argininosuccinic aciduria in France in USD Million (2017–2030)

Table 28: France Market Size of ASA by Therapies, in USD Million (2017–2030)

Table 29: Total Market Size of Argininosuccinic aciduria in Italy in USD Million (2017–2030)

Table 30: Italy Market Size of ASA by Therapies, in USD Million (2017–2030)

Table 31: Total Market Size of Argininosuccinic aciduria in Spain in USD Million (2017–2030)

Table 32: Spain Market Size of ASA by Therapies, in USD Million (2017–2030)

Table 33: Total Market Size of Argininosuccinic aciduria in the UK in USD Million (2017–2030)

Table 34: The UK Market Size of ASA by Therapies, in USD Million (2017–2030)

Table 35: Total Market Size of Argininosuccinic aciduria in Japan in USD Million (2017–2030)

Table 36:Japan Market Size of ASA by Therapies, in USD Million (2017–2030)

List of Figures

 Figure 1: Systemic phenotype in Argininosuccinic aciduria

Figure 2: The Urea Cycle

Figure 3: Pathophysiological mechanisms in Argininosuccinic Aciduria

Figure 4: Stepwise diagnostic procedure for investigational hyperammonemia

Figure 5: Total Incident Population of ASA in 7MM (2017–2030)

Figure 6: Total Incident Cases of ASA in the US (2017–2030)

Figure 7: Early-onset and Late-onset Cases of ASA in the US (2017–2030)

Figure 8: Total Incident Cases of ASA in Germany (2017–2030)

Figure 9: Early-onset and Late-onset Cases of ASA in Germany (2017–2030)

Figure 10: Total Incident Cases of ASA in France (2017–2030)

Figure 11: Early-onset and Late-onset Cases of ASA in France (2017–2030)

Figure 12: Total Incident Cases of ASA in Italy (2017–2030)

Figure 13: Early-onset and Late-onset Cases of ASA in Italy (2017–2030)

Figure 14: Total Incident Cases of ASA in Spain (2017–2030)

Figure 15: Early-onset and Late-onset Cases of ASA in Spain (2017–2030)

Figure 16: Total Incident Cases of ASA in the UK (2017–2030)

Figure 17: Early-onset and Late-onset Cases of ASA in the UK (2017–2030)

Figure 18: Total Incident Cases of ASA in Japan (2017–2030)

Figure 19: Early-onset and Late-onset Cases of ASA in Japan (2017–2030)

Figure 20: Unmet Needs

Figure 21: Market Size of Argininosuccinic aciduria in USD Million (2017–2030)

Figure 22: Total Market Size of Argininosuccinic aciduria in the US, USD Millions (2017–2030)

Figure 23: The US Market Size of ASA by Therapies, USD Millions (2017–2030)

Figure 24: Total Market Size of Argininosuccinic aciduria in Germany, USD Millions (2017–2030)

Figure 25: Germany Market Size of ASA by Therapies, USD Millions (2017–2030)

Figure 26: Total Market Size of Argininosuccinic aciduria in France, USD Millions (2017–2030)

Figure 27: France Market Size of ASA by Therapies, USD Millions (2017–2030)

Figure 28: Total Market Size of Argininosuccinic aciduria in Italy, USD Millions (2017–2030)

Figure 29: Italy Market Size of ASA by Therapies, USD Millions (2017–2030)

Figure 30: Total Market Size of Argininosuccinic aciduria in Spain, USD Millions (2017–2030)

Figure 31: Spain Market Size of ASA by Therapies, USD Millions (2017–2030)

Figure 32: Total Market Size of Argininosuccinic aciduria in the UK, USD Millions (2017–2030)

Figure 33: The UK Market Size of ASA by Therapies, USD Millions (2017–2030)

Figure 34: Total Market Size of Argininosuccinic aciduria in Japan, USD Millions (2017–2030)

Figure 35: Japan Market Size of ASA by Therapies, USD Millions (2017–2030)

Figure 36: Market Drivers

Figure 37:Market Barriers

Horizon Therapeutics

Acer Therapeutics

Evox Therapeutics

  • Tags:
  • Argininosuccinic aciduria (ASA) mar...
  • Argininosuccinic aciduria (ASA) ma...
  • Argininosuccinic aciduria (ASA) m...
  • Argininosuccinic aciduria (ASA) ma...
  • Argininosuccinic aciduria (ASA) ma...
  • Argininosuccinic aciduria (ASA) ma...
  • Argininosuccinic aciduria (ASA) pi...
  • Argininosuccinic aciduria (ASA) t...
  • Argininosuccinic aciduria (ASA) d...
  • Argininosuccinic aciduria (ASA) sa...
  • Argininosuccinic aciduria (ASA) ma...
  • Argininosuccinic aciduria (ASA) di...
  • Argininosuccinic aciduria (ASA) epi...
  • Argininosuccinic aciduria (ASA)

Forward to Friend

Need A Quote